WO2002074907A3 - Methods of modulating surfactant production - Google Patents

Methods of modulating surfactant production Download PDF

Info

Publication number
WO2002074907A3
WO2002074907A3 PCT/US2002/005134 US0205134W WO02074907A3 WO 2002074907 A3 WO2002074907 A3 WO 2002074907A3 US 0205134 W US0205134 W US 0205134W WO 02074907 A3 WO02074907 A3 WO 02074907A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
fas
disease
polypeptides
treatment
Prior art date
Application number
PCT/US2002/005134
Other languages
French (fr)
Other versions
WO2002074907A2 (en
Inventor
Robert James Mason
Steven Neben
Michael R Eckart
Malinda Longphre
Original Assignee
Bayer Ag
Robert James Mason
Steven Neben
Michael R Eckart
Malinda Longphre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Robert James Mason, Steven Neben, Michael R Eckart, Malinda Longphre filed Critical Bayer Ag
Priority to AU2002258403A priority Critical patent/AU2002258403A1/en
Publication of WO2002074907A2 publication Critical patent/WO2002074907A2/en
Publication of WO2002074907A3 publication Critical patent/WO2002074907A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01085—Fatty-acid synthase (2.3.1.85)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of modulating surfactant production using FAS polypeptides, and agonists or antagonists that are capable of modulating FAS activity. More particularly, the present invention encompasses the use of FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
PCT/US2002/005134 2001-02-02 2002-01-30 Methods of modulating surfactant production WO2002074907A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002258403A AU2002258403A1 (en) 2001-02-02 2002-01-30 Methods of modulating surfactant production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26597901P 2001-02-02 2001-02-02
US60/265,979 2001-02-02

Publications (2)

Publication Number Publication Date
WO2002074907A2 WO2002074907A2 (en) 2002-09-26
WO2002074907A3 true WO2002074907A3 (en) 2002-11-21

Family

ID=23012668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005134 WO2002074907A2 (en) 2001-02-02 2002-01-30 Methods of modulating surfactant production

Country Status (2)

Country Link
AU (1) AU2002258403A1 (en)
WO (1) WO2002074907A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519818A (en) * 2011-05-10 2014-08-21 ニュークレア バイオテクノロジーズ インコーポレイテッド Predictive biomarkers for prostate cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000051430A1 (en) * 1999-03-03 2000-09-08 Smithkline Beecham Corporation Human fas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000051430A1 (en) * 1999-03-03 2000-09-08 Smithkline Beecham Corporation Human fas
US6294364B1 (en) * 1999-03-03 2001-09-25 Smithkline Beecham Corporation Human FAS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAYUKUMAR ET AL.: "Human fatty acid synthase: properties and molecular cloning", PROC. NATL. ACAD. SCI. USA, vol. 92, no. 19, September 1995 (1995-09-01), pages 8695 - 8699, XP002195434 *

Also Published As

Publication number Publication date
AU2002258403A1 (en) 2002-10-03
WO2002074907A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
GB0324654D0 (en) Medicinal compounds
DE60105807D1 (en) Process for the preparation of a stable pharmaceutical composition containing micronized formoterol
AP1712A (en) Novel tiotropium-containing inhalation powder
EA200401005A1 (en) DOSED INHALERS UNDER PRESSURE CONTAINING BETA-2-AGONIST SOLUTIONS
NO20025221D0 (en) New preparation
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2005058867A8 (en) Benzothiophene-and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders
NO20024708L (en) Treatment of respiratory diseases
UA83813C2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
ATE541570T1 (en) COMBINATION OF ANTICHOLINERGICS AND PHOSPHODIESTERASE TYPE 4 INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2003020313A1 (en) Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
AU2006329199A8 (en) Treatment of respiratory diseases
WO2004041272A3 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
CN102803285A (en) Pharmaceutical composition comprising a steroidal[3,2-c]pyrazole derivative and a second pharmaceutically active compound
RS20060293A (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
HUP0400222A2 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
WO2002074907A3 (en) Methods of modulating surfactant production
WO2002095008A3 (en) Methods of modulating surfactant phospholipid production
WO2002078618A3 (en) Methods of modulating surfactant production
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
RS20050400A (en) Pulverulent formulation for inhalation containing tiotropium
MXPA04007294A (en) Composition for inhalation.
DE602005022558D1 (en) MICROEMULSION FORMULATIONS WITH SPECIFIC SUBSTANCE P ANTAGONISTS
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2001010423A3 (en) Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP